Table 2.

Bivariate and mutivariable analyses link FMD with CMV antibodies at V60 in HIV patients, and with sTNFR in healthy controls

Panel A	HIV (V0)	HIV (V60)	HC
Age		− 0.18	− 0.06
BMI		− 0.005	− 0.32b
CD4 T-cells	− 0.09	0.010	0.09
Ln sTNFR	0.05	0.13	− 0.41a
Ln CRP	− 0.07	− 0.08	− 0.22b
Ln ICAM-1	− 0.003	0.07	− 0.26b
Ln CMV IE-1 antibody	− 0.19	0.17	0.06
Ln CMV lysate antibody	− 0.007	− 0.37a	− 0.14
Ln CMV gB antibody	− 0.17	0.02	0.21b
Chondroitin sulphate	− 0.06	− 0.29b	− 0.30b

Panel B	β coefficient	95% CI	P
Prediction of FMD in HIV patients at V60; Adjusted R2 = 0.214, p = 0.012
Ln CMV lysate antibody	− 1.43	− 2.52 to − 0.34	0.012
Chondroitin sulphate	− 0.15	− 0.29 to − 0.01	0.035
Prediction of FMD in healthy controls; Adjusted R2 = 0.248, p = 0.013
Ln sTNFR	− 7.31	− 13.04 to − 1.58	0.014
Ln CMV gB antibody	1.53	− 0.05 to 3.10	0.056
Chondroitin sulphate	− 0.16	− 0.37 to 0.05	0.136

Panel A presents Pearson’s r values assessing correlations with FMD

^a p value < 0.05

^bp values of 0.05 to 0.25 were used to select parameters for the multivariable analyses

Panel B summarises the optimal multivariable models predicting FMD